Staidson (300204.SZ) STSA-1002 Injection (Indications for Acute Respiratory Distress Syndrome) Received Summary Report of Phase Ib II Clinical Study.
Shutai Shen (300204.SZ) Announcement: The company recently obtained information about STSA-1002 injectable solution (acute respiratory ...
Staidson (300204.SZ) announced that the company recently obtained the summary report of the Ib/II clinical study on STSA-1002 injection (indication for Acute Respiratory Distress Syndrome). The STSA-1002 injection showed preliminary effectiveness and good safety in the Ib/II study, supporting further clinical research.
Related Articles
FORTIOR (01304) Hong Kong public offering oversubscribed by 138.26 times, with an offer price of 120.5 Hong Kong dollars per share.
ACESO LIFE SCI(00474) recently sold a total of 13.872 million shares of Heaven Intelligence Co., Ltd.
US Stock Market Move | Wolfspeed (WOLF.US) continues to rise, with the stock price up more than 12%.
FORTIOR (01304) Hong Kong public offering oversubscribed by 138.26 times, with an offer price of 120.5 Hong Kong dollars per share.
ACESO LIFE SCI(00474) recently sold a total of 13.872 million shares of Heaven Intelligence Co., Ltd.
US Stock Market Move | Wolfspeed (WOLF.US) continues to rise, with the stock price up more than 12%.
RECOMMEND
Li Ning Faces Sharp Decline in Market Value Amid Strategic Uncertainty and Brand Challenges
08/07/2025
First Batch of Copper Arrives in Hong Kong Warehouses, to Join LME Global Storage Network
08/07/2025
NDRC and Three Departments Jointly Issue Notice to Advance Grid Construction and High-Power Charging Infrastructure Development
08/07/2025
